Zoetis Announces Pricing of $1.85 Billion of Senior Notes
Zoetis intends to use the net proceeds to repay the principal of (i) its 4.500% senior notes due 2025 in the aggregate principal amount of $750 million, (ii) its 5.400% senior notes due 2025 in the aggregate principal amount of $600 million, and (iii) the remainder for general corporate purposes. The offering is expected to close on August 18, 2025, subject to customary closing conditions.
Barclays Capital Inc., BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters. The final prospectus supplement and accompanying prospectus, when available, may be accessed through the SEC's website at www.sec.gov. Alternatively, the issuer, the underwriters or any dealer participating in the offering will arrange to send the prospectus and prospectus supplement upon request by calling Barclays at 1-888-603-5847, BofA Securities at 1-800-294-1322, Citigroup at 1-800-831-9146, J.P. Morgan at 212-834-4533 and MUFG at 1-877-649-6848.
These securities are offered pursuant to a registration statement that has become effective under the Securities Act of 1933, as amended. These securities are only offered by means of the prospectus supplement and prospectus relating to the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or other jurisdiction, where the offer, solicitation or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Zoetis
As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned 'Forward-Looking Statements and Factors That May Affect Future Results' and 'Item 1A. Risk Factors,' in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov or on request from Zoetis.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Why Resideo (REZI) Stock Is Trading Up Today
What Happened? Shares of home automation and security solutions provider Resideo Technologies (NYSE:REZI) jumped 12.9% in the afternoon session after an upgrade from Morgan Stanley, which raised its rating on the stock to Overweight from Equal-Weight. The investment bank boosted its price target to $35 from a previous $24. The upgrade was driven by several positive developments, including Resideo's strong second-quarter results, which surpassed the high end of guidance and marked the best organic revenue growth in 15 quarters. Additionally, analysts highlighted the recent cancellation of a "longstanding and complex" indemnification agreement with Honeywell. This move is seen as removing a significant structural barrier for investors and creating a clearer path to what Morgan Stanley estimates could be approximately $3 in earnings power. The company's plan to separate its ADI Global distribution business in 2026 was also noted as a potential catalyst for unlocking shareholder value. Is now the time to buy Resideo? Access our full analysis report here, it's free. What Is The Market Telling Us Resideo's shares are quite volatile and have had 17 moves greater than 5% over the last year. But moves this big are rare even for Resideo and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 6 days ago when the stock gained 7.5% on the news that the company reported record second-quarter financial results that beat analyst expectations and raised its full-year guidance. The company posted record revenue of $1.94 billion, a 22% increase from the previous year, and adjusted earnings per share of $0.66. These figures surpassed Wall Street's forecasts. While Resideo recorded a net loss of $825 million, this resulted from a one-time expense to end an agreement with Honeywell. Investors appeared to focus on the strong operational performance, as both its Products and Solutions and ADI segments achieved organic revenue growth. In a sign of confidence, the company also lifted its full-year 2025 financial outlook and announced plans to spin off its ADI business segment. Resideo is up 37% since the beginning of the year, and at $31.21 per share, has set a new 52-week high. Investors who bought $1,000 worth of Resideo's shares 5 years ago would now be looking at an investment worth $2,255. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Why Hubbell (HUBB) Stock Is Up Today
What Happened? Shares of electrical and electronic products company Hubbell (NYSE:HUBB) jumped 3.2% in the afternoon session after it agreed to acquire DMC Power, a provider of electrical grid components, for $825 million in cash. DMC Power provides critical connectors and tooling for utility substation and transmission markets. Hubbell's management stated the deal expands its presence in attractive markets, driven by growing power demand from datacenter buildouts and the need to upgrade aging infrastructure. The acquisition is expected to close by the end of 2025 and begin contributing to Hubbell's adjusted earnings per share in 2026. Supporting the stock's move was a broader rally in the Industrials sector, fueled by a favorable inflation report which raised hopes for a Federal Reserve interest rate cut. After the initial pop the shares cooled down to $432.24, up 3.5% from previous close. Is now the time to buy Hubbell? Access our full analysis report here, it's free. What Is The Market Telling Us Hubbell's shares are not very volatile and have only had 7 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 14 days ago when the stock dropped 3.2% on the news that the company reported mixed second-quarter financial results, where a miss on revenue overshadowed a strong earnings beat. The electrical products manufacturer posted revenue of $1.48 billion, which fell short of analysts' consensus estimates of $1.51 billion. This top-line miss appeared to concern investors more than the company's otherwise strong bottom-line performance. Hubbell reported adjusted earnings of $4.93 per share, significantly surpassing Wall Street expectations. Furthermore, the company raised its full-year earnings guidance to a range of $17.65 to $18.15 per share. Despite the positive earnings and improved outlook, the market's reaction suggested that the slowdown in sales growth weighed heavily on sentiment. Hubbell is up 2.9% since the beginning of the year, and at $432.24 per share, it is trading close to its 52-week high of $472.12 from November 2024. Investors who bought $1,000 worth of Hubbell's shares 5 years ago would now be looking at an investment worth $2,939. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
DDD Q2 Deep Dive: Cost Actions Offset Revenue Decline as Tariffs Disrupt Demand
3D printing company 3D Systems (NYSE:DDD) fell short of the market's revenue expectations in Q2 CY2025, with sales falling 16.3% year on year to $94.84 million. Its non-GAAP loss of $0.07 per share was 54.8% above analysts' consensus estimates. Is now the time to buy DDD? Find out in our full research report (it's free). 3D Systems (DDD) Q2 CY2025 Highlights: Revenue: $94.84 million vs analyst estimates of $95.78 million (16.3% year-on-year decline, 1% miss) Adjusted EPS: -$0.07 vs analyst estimates of -$0.16 (54.8% beat) Adjusted EBITDA: -$4.41 million vs analyst estimates of -$13.67 million (-4.6% margin, 67.8% beat) Operating Margin: -16.2%, up from -23.3% in the same quarter last year Market Capitalization: $225.7 million StockStory's Take 3D Systems' results in Q2 reflected ongoing challenges from weakened customer capital spending and tariff uncertainty, but the market reacted positively as the company delivered significant improvements in cost control and profitability measures. Management attributed the 16% year-over-year sales decline primarily to customers delaying new production capacity investments amid volatile tariffs and global economic uncertainty. CEO Jeffrey Graves highlighted that sequential revenue excluding the divested software business grew 8%, pointing to stabilization and the early benefits of strategic restructuring and operational efficiencies. In particular, cost reductions and in-sourcing initiatives helped narrow operating losses and strengthen margins. Looking ahead, 3D Systems' guidance is shaped by continued focus on cost alignment, new product launches, and sector-specific growth opportunities in medical and aerospace markets. Management expects ongoing margin improvement through further operational streamlining and automation, while highlighting the ramp-up of FDA-cleared dental products and expansion in MedTech as drivers for future growth. CEO Jeffrey Graves noted, 'Our top priority is to align our costs with current market conditions in order to move to positive cash flow in 2026,' emphasizing disciplined investment in high-ROI R&D and targeted commercialization efforts despite ongoing macro headwinds. Key Insights from Management's Remarks Management saw Q2 performance shaped by aggressive restructuring, sector-specific product momentum, and the impact of tariffs on customer spending decisions. Cost restructuring accelerated: 3D Systems implemented broad cost reduction actions, including process automation and consolidation of facilities, targeting over $85 million in annualized savings by mid-2026. These moves have already yielded a 27% year-over-year reduction in operating expenses and improved margins, though management cautioned about timing risks related to facility subleasing. Healthcare segment highlights: The MedTech business, encompassing orthopedic solutions, surgical guides, and point-of-care services, grew 13% year-over-year and 16% sequentially. Management cited strong demand for personalized medical devices, particularly for above-the-neck trauma and cancer applications, as a key factor in the segment's resilience. Dental launches and market expansion: The company rolled out its NextDent Jetted Denture Solution, an FDA-cleared product targeting the U.S. market for dental prosthetics. Management sees this as a significant growth opportunity, with early purchase orders and plans for expanded regulatory approvals globally in the coming year. Aerospace and defense momentum: The Aerospace business nearly doubled its annualized revenues, driven by application wins in both the U.S. and Europe. 3D Systems' metal printing platforms have gained traction in high-reliability markets such as aerospace, defense, and AI infrastructure, supporting the company's "3P" strategy (process, parts, printers). Tariffs and CapEx delays: Customers remain hesitant to invest in new printing capacity due to ongoing tariff volatility, causing delays in printer sales but increasing demand for limited-quantity part production. Management is using this period to bridge customers from process development through small-batch production until capital spending resumes. Drivers of Future Performance Management expects near-term results to be shaped by disciplined cost execution, new product commercialization in healthcare, and ongoing macroeconomic and tariff-related headwinds. Margin improvement focus: The company aims to reach positive cash flow in 2026 by further reducing operating expenses, streamlining back-office functions, and consolidating global manufacturing. Operational efficiency gains from in-sourcing and automation are expected to offset rising component costs due to tariffs. Healthcare and dental product scaling: Expansion of MedTech offerings and ramp-up of the NextDent denture solution are seen as primary growth drivers. Management expects regulatory approvals and broader market penetration in dental to increase healthcare revenue mix and support sustainable growth. Tariff and CapEx uncertainty: Persistent uncertainty around tariffs continues to delay large capital equipment purchases by customers, particularly in industrial markets. While this creates near-term headwinds for printer sales, management is leveraging its ability to provide limited-run parts and services as a bridge, with the expectation that demand for new equipment will rebound once the tariff environment stabilizes. Catalysts in Upcoming Quarters In the coming quarters, StockStory analysts will closely monitor (1) the pace of cost reductions and whether operating expenses reach management's targeted range, (2) the commercial uptake and regulatory progress of the NextDent Jetted Denture Solution in both the U.S. and international markets, and (3) sustained growth in MedTech and Aerospace revenues despite ongoing macro headwinds. Execution on facility consolidation and visibility into customer CapEx recovery will also serve as key indicators of future performance. 3D Systems currently trades at $2.25, up from $1.75 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it's free). Now Could Be The Perfect Time To Invest In These Stocks When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
